Bristol-Myers Can't Dodge Celgene Investors' Drug Delay Suit
By Craig Clough · June 24, 2022, 10:16 PM EDT
UMB Bank can pursue its claims that Bristol-Myers Squibb improperly delayed U.S. Food and Drug Administration approval of a cancer treatment to avoid paying $6.4 billion owed from a 2019 acquisition...
To view the full article, register now.